Liposome induction or enhancement of macrophage-mediated cancer cell lysis.
Liposomes of different composition have been used to modify macrophage-mediated destruction of syngeneic cancer cells through a modulation of membrane lipid content of macrophages and/or tumor cells. Dipalmitoylphosphatidylcholine (DPPC)1 liposomes induce cancer cell lysis by normal, non-tumoricidal, peritoneal macrophages and enhance tumor cell destruction by BCG-activated macrophages. This effect was produced by large and small unilamellar liposomes, which are in the 25,000 g supernatant of sonicated preparations. Addition of cholesterol or negative charges carried by dicetylphosphate supressed the effect of DPPC liposomes on macrophage-mediated cytolysis. Enhancement of macrophage-mediated tumor cell lysis was observed when both cancer cells and macrophages were incubated with DPPC liposomes, but not when macrophages and/or tumor cells were preincubated with liposomes prior to their coincubation. Liposomes did not promote the binding of the cancer cells to the macrophages. Liposomes could promote formation of phospholipid domains within the plasma membrane of both tumor cells and macrophages leading to the destruction of cancer cells through a temporary fusion with the macrophages.
D000818:Animals; D002460:Cell Line; D066298:In Vitro Techniques; D008081:Liposomes / Q000276:immunology*; D008262:Macrophage Activation; D008264:Macrophages / Q000276:immunology*; D009374:Neoplasms, Experimental / Q000276:immunology*; D011663:Pulmonary Surfactants; D051381:Rats
D008081:Liposomes; D011663:Pulmonary Surfactants